搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
中华网
23 小时
制药巨头双抗业务版图:罗氏领跑,强生三面进击,阿斯利康 ...
这其中也不乏制药巨头的重量级押注。8月,默沙东以7亿美元的首付款将同润生物一款处于I期阶段的CD3/CD19双抗CN201收入囊中。7月,诺华与Dren Bio就髓系细胞募集双抗的开发达成合作,交易总额达30亿美元。
18 小时
on MSN
New CAR-T cells offer on-demand control for cancer treatment
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer ...
technologynetworks
9 小时
CAR-T Cells Offer Remote Control for Cancer Therapy
Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy.
7 小时
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈